Hyaluronic acid-based nanocarriers for intracellular targeting: Interfacial interactions with proteins in cancer

被引:212
作者
Choi, Ki Young [2 ,3 ]
Saravanakumar, Gurusamy [4 ]
Park, Jae Hyung [4 ]
Park, Kinam [1 ,2 ]
机构
[1] Purdue Univ, Weldon Sch Biomed Engn, Dept Biomed Engn, W Lafayette, IN 47907 USA
[2] Purdue Univ, Dept Pharmaceut, W Lafayette, IN 47907 USA
[3] NIBIB, Lab Mol Imaging & Nanomed LOMIN, NIH, Bethesda, MD 20892 USA
[4] Sungkyunkwan Univ, Dept Polymer Sci & Engn, Suwon 440746, South Korea
关键词
Hyaluronic acid; Tumor targeting; Intracellular targeting; Nanocarrier; Drug delivery; Tumor imaging; RECEPTOR-MEDIATED ENDOCYTOSIS; HUMAN BREAST-CANCER; ANCHORAGE-INDEPENDENT GROWTH; TUMOR-DERIVED HYALURONIDASE; CD44 SPLICE VARIANTS; IN-VIVO; DRUG-DELIVERY; PROSTATE-CANCER; BLADDER-CANCER; EXTRACELLULAR-MATRIX;
D O I
10.1016/j.colsurfb.2011.10.029
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The therapeutic efficacy of most drugs is greatly depends on their ability to cross the cellular barrier and reach their intracellular target sites. To transport the drugs effectively through the cellular membrane and to deliver them into the intracellular environment, several interesting smart carrier systems based on both synthetic or natural polymers have been designed and developed. In recent years, hyaluronic acid (HA) has emerged as a promising candidate for intracellular delivery of various therapeutic and imaging agents because of its innate ability to recognize specific cellular receptors that overexpressed on diseased cells. The aim of this review is to highlight the significance of HA in cancer, and to explore the recent advances of HA-based drug carriers towards cancer imaging and therapeutics. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:82 / 94
页数:13
相关论文
共 171 条
[1]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[2]   CD44 IS THE PRINCIPAL CELL-SURFACE RECEPTOR FOR HYALURONATE [J].
ARUFFO, A ;
STAMENKOVIC, I ;
MELNICK, M ;
UNDERHILL, CB ;
SEED, B .
CELL, 1990, 61 (07) :1303-1313
[3]  
ASPLUND T, 1993, CANCER RES, V53, P388
[4]  
Assmann V, 1999, J CELL SCI, V112, P3943
[5]   Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival [J].
Auvinen, P ;
Tammi, R ;
Parkkinen, J ;
Tammi, M ;
Ågren, U ;
Johansson, R ;
Hirvikoski, P ;
Eskelinen, M ;
Kosma, VM .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (02) :529-536
[6]   Hyaluronic acid-paclitaxel: Antitumor efficacy against CD44(+) human ovarian carcinoma xenografts [J].
Auzenne, Edmond ;
Ghosh, Sukhen C. ;
Khodadadian, Mojgan ;
Rivera, Belinda ;
Farquhar, David ;
Price, Roger E. ;
Ravoori, Murali ;
Kundra, Vikas ;
Freedman, Ralph S. ;
Klostergaard, Jim .
NEOPLASIA, 2007, 9 (06) :479-486
[7]   LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan [J].
Banerji, S ;
Ni, J ;
Wang, SX ;
Clasper, S ;
Su, J ;
Tammi, R ;
Jones, M ;
Jackson, DG .
JOURNAL OF CELL BIOLOGY, 1999, 144 (04) :789-801
[8]   Expression of PH-20 in normal and neoplastic breast tissue [J].
Beech, DJ ;
Madan, AK ;
Deng, N .
JOURNAL OF SURGICAL RESEARCH, 2002, 103 (02) :203-207
[9]   Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma:: Relationship with tumor aggressiveness [J].
Bertrand, P ;
Courel, MN ;
Maingonnat, C ;
Jardin, F ;
Tilly, H ;
Bastard, C .
INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (02) :207-212
[10]  
Bertrand P, 1997, INT J CANCER, V73, P327, DOI 10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO